Jacob Sterling

@NUFeinbergMed IM PSTP & Thomson Lab Post Doc | @Penn MD-PhD | Cardiovascular Immunologist with a penchant for the CNS

[Jacob Sterling @jacobksterling]

@RiderToast @EllenWhiteinLab @HarrisOnTheSkin Gotta call out the gold diggers among us

[Jacob Sterling @jacobksterling]

@RiderToast @EllenWhiteinLab @HarrisOnTheSkin

[Neil Stone @DrNeilStone]

PDFs of journal articles that I will "read later"

[Jacob Sterling @jacobksterling]

When did George Lucas start interning for the @nytimes digital team?

[Jacob Sterling @jacobksterling]

Between the shade from sidewalk greenery and a dedicated cycling lane everyone would walk/bike to work and the need for GLP-1R agonists, bariatric surgery, et al. would plummet. As much as I love a medical therapeutic solution, maybe we should just design cities for… people?

[Hayden @the_transit_guy]

This would be my platform as president:

[Reseau Vision @ReseauVision]

Ne ratez pas cet évènement! Rappel pour le 2e Symposium sur l’angiogenèse rétinienne et choroïdienne (Montréal) JEUDI, 20 OCTOBRE 2022. https://t.co/wkw15LkduD
Inscriptions prolongées jusqu’au 7 OCTOBRE (en personne) et 14 OCTOBRE (Zoom). @ReseauVision @FRQS1 @med_umontreal

[Waggoner Lab @LabWaggoner]

Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
https://t.co/ZROHNyv7QA

[ScienceInsider @ScienceInsider]

BREAKING: White House issues new policy that will require, by 2026, all federally-funded research results to be freely available to public without delay, ending longstanding ability of journals to paywall results for up to 1 year. Coverage coming on @ScienceInsider.

[Sanjee Baksh @S__Baksh]

Neutrophils sacrificing themselves to help fight infections... idk to me, that's really hematopoetic

[Scott Tyler (@[email protected]) @ScienceScottT]

I don't know if I can keep reading single cell papers...😅🤣

[The Lens: Ophthalmology Research Newsletter @TheLens_oph]

A recent @BMJ_Ophth study by @jacobksterling and colleagues found that a medications used for diabetics may be useful in treating and preventing #glaucoma! #ophthalmology #glaucoma
Read more: https://t.co/c8VbwPcNpz
#medtwitter #Ophthalmology #eyes

[Jacob Sterling @jacobksterling]

Please.

[Dr. Len Zon @leonard_zon]

The Zon lab is excited to present a method to avoid reformatting of papers with every submission to a new journal. We feel this will save time for scientists.
A uniform format for manuscript submission https://t.co/zegOpI9BB2

[Jacob Sterling @jacobksterling]

@GFPtagged I wouldn’t have anything else to present if I didn’t include this. It’s less a defense, more a performance art piece where my committee and I watch this clip on repeat for two hours.

[Jacob Sterling @jacobksterling]

For the record - this, the most significant output of my PhD, was accomplished in parallel with a rather complicated cell sort that failed miserably

[Qi Cui, MD PhD 👁 @CuiLab]

Don't think I'm exaggerating when I say this is one of the best things to come out of the Dunaief and Cui labs. Courtesy of @jacobksterling (who clearly needs another 10 projects on top of the 20 he's already pursuing) 😉🎤🎶

[Jacob Sterling @jacobksterling]

Can’t wait to get back to clerkships!

[Jesse Weber @Jesswebz]

Me after going downstairs in lab to check on the new mice pups that dropped yesterday, only to find out that the mother went full hungry hungry hippo on the kids

[Joel M. Topf, MD FACP @kidney_boy]

The arc of history bends toward justice

[Jacob Sterling @jacobksterling]

Thank you to @ScheieEye @RPB_org @NIH @NatEyeInstitute for their support on this project!

[Jacob Sterling @jacobksterling]

@CuiLab's latest preprint out now!

tl;dr GLP-1R agonist use is reduces risk of glaucoma among patients with T2DM. Tweetorial discussing the results in context of our ongoing work below.

[medRxiv @medrxivpreprint]

Exposure to glucagon-like peptide 1 receptor (GLP-1R) agonists reduces glaucoma risk. https://t.co/bhzgR3Qtoz #medRxiv

[Jacob Sterling @jacobksterling]

While this certainly helps build the case for a future GLP-1R agonist trial for glaucoma, it also provides an impetus for providers to consider GLP-1R agonists as preferred therapy for diabetic patients at high risk of glaucoma.